Clinical Trial Optimization: Smarter Enrollment. Stronger Analysis. Proven Results.
Maximize Power and Efficiency from First Patient In to Final OutcomeOrigent partners with biopharma and CROs to de-risk and accelerate clinical trials through validated predictive modeling. Our solutions optimize enrollment criteria, identify the right patients sooner, and deliver robust comparative analyses — even when traditional control groups are limited. The result: lower costs, greater statistical power, and a clearer path to approval. Our models reduce trial risk and cost — driving faster, more confident ROI for sponsors and partners.
Optimized Enrollment, Virtual Controls, and Drug Rescue
Smarter Enrollment – Origent’s predictive modeling makes enrollment faster and more reliable. By forecasting individual patient trajectories, we help sponsors refine inclusion and exclusion criteria, identify high-fit participants sooner, and reduce screen failures. This ensures study arms are balanced and each enrolled patient contributes meaningful data, saving both time and cost.
Virtual Controls and Subgroup Analysis – Our platform strengthens trials with advanced analytical tools that go beyond conventional approaches. When traditional placebo groups are not feasible, our Virtual Control Arms provide robust comparative benchmarks. In addition, our Detectable Effect Cluster (DEC) technology uncovers hidden responder subgroups within heterogeneous patient populations, guiding smarter trial design and follow-up studies.
Faster, Cost-Effective Trials – By integrating smarter enrollment, virtual controls, and subgroup detection, Origent helps sponsors run smaller, more efficient studies with clearer endpoints. This reduces the risk of costly late-stage failures and accelerates time to market. For developers and investors, it means higher confidence in trial outcomes, better resource allocation, and improved return on investment.